RSCM
DRNA

Rock Springs Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Rock Springs Capital Management’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-105,000
Closed -$2.97M – 91
2014
Q1 		$2.97M Buy
+105,000
New +$3.9M 0.68% 47

Other funds holding DRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Rock Springs Capital Management's DRNA Position: Q2 2014 in Review

Rock Springs Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q2 2014, closing a stake of 105,000 shares — an estimated $2.97M sold.

Rock Springs Capital Management first reported a position in DRNA in Q1 2014 and held it in 1 quarter. The position peaked at $2.97M in Q1 2014. 41 funds tracked by Wall St. Rank hold DRNA as of Q2 2014.

  • Rock Springs Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
  • Rock Springs Capital Management sold 105,000 Dicerna Pharmaceuticals, Inc. shares in Q2 2014, an estimated $2.97M.
  • Rock Springs Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2014 and held it in 1 quarter.
  • Rock Springs Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $2.97M in Q1 2014.
  • 41 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q2 2014.

Based on Rock Springs Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.